Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;13(16):2381-95.
doi: 10.1517/14656566.2012.725722. Epub 2012 Sep 20.

Dasatinib for the treatment of Philadelphia chromosome-positive leukemias

Fabio P S Santos  1 , Jorge Cortes
Affiliations
Review

Dasatinib for the treatment of Philadelphia chromosome-positive leukemias

Fabio P S Santos et al. Expert Opin Pharmacother. 2012 Nov.

Abstract

Introduction: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI), which was developed to treat patients with chronic myelogenous leukemia (CML), who had failed or were intolerant to therapy with imatinib.

Areas covered: In this article, we review preclinical and clinical studies with dasatinib for the therapy of Philadelphia (Ph)-positive leukemias.

Expert opinion: Dasatinib is very effective in the setting of CML resistance or intolerance to imatinib, particularly in patients in chronic phase (CP). Dasatinib is also effective against most BCR-ABL1 mutations that arise during therapy with imatinib. Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL). More recently, randomized trials have demonstrated that dasatinib is superior to imatinib in the initial therapy of patients with CML, and the drug was approved by the FDA for this indication in 2011.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers.
    Sourbier C, Liao PJ, Ricketts CJ, Wei D, Yang Y, Baranes SM, Gibbs BK, Ohanjanian L, Spencer Krane L, Scroggins BT, Keith Killian J, Wei MH, Kijima T, Meltzer PS, Citrin DE, Neckers L, Vocke CD, Marston Linehan W. Sourbier C, et al. Oncotarget. 2018 Jan 10;9(12):10723-10733. doi: 10.18632/oncotarget.24112. eCollection 2018 Feb 13. Oncotarget. 2018. PMID: 29535838 Free PMC article.
  • A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy.
    Wang H, Zhang Y, Zeng X, Pei W, Fan R, Wang Y, Wang X, Li J. Wang H, et al. Int J Nanomedicine. 2021 Mar 23;16:2373-2388. doi: 10.2147/IJN.S299681. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33790555 Free PMC article.
  • Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
    Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group. Rousselot P, et al. Blood. 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27. Blood. 2016. PMID: 27121472 Free PMC article.
  • Anti-Angiogenic Activity of Drugs in Multiple Myeloma.
    Saltarella I, Altamura C, Campanale C, Laghetti P, Vacca A, Frassanito MA, Desaphy JF. Saltarella I, et al. Cancers (Basel). 2023 Mar 27;15(7):1990. doi: 10.3390/cancers15071990. Cancers (Basel). 2023. PMID: 37046651 Free PMC article. Review.

MeSH terms

LinkOut - more resources